PMC4900121_01
42-year-old woman with hidradenitis suppurativa. A) Left MLO view shows an asymmetry in the region of the palpable marker. B) Spot compression of the area shows that the lesion persists. C) Tangential view demonstrates the subcutaneous locations of the lesion.
gr1.jpg
PMC4900121_01_gr1.jpg
fig1
Mammography demonstrated a 1.1-cm skin-based lesion in the left axilla (Fig. 1).
42-year-old woman with hidradenitis suppurativa. Transverse color Doppler ultrasound shows a superficial oval mass in the left axillary region with  evidence of peripheral blood flow.
gr2.jpg
PMC4900121_01_gr2.jpg
fig2
Followup breast sonography three months later demonstrated a palpable hypoechoic, irregular, parallel lesion with central echogenic material and associated peripheral vascularity located within the skin, in the same area as a prior cyst (Fig. 2).
42-year-old woman with hidradenitis suppurativa. Transverse color Doppler ultrasound shows a hypoechoic superficial oval mass in the left axillary region with evidence of peripheral blood flow.
gr3.jpg
PMC4900121_01_gr3.jpg
fig3
A second new intradermal hypoechoic, oval, parallel, cystic lesion, possibly representing a sebaceous cyst or new HS lesion, was also identified adjacent to the known lesion (Fig. 3).
42-year-old woman with hidradenitis suppurativa. A new subcutaneous mass was noted in the right axillary region. A) Transverse grayscale ultrasound shows a superficial oval hypoechoic mass with a parallel orientation. B) Color Doppler ultrasound shows evidence of flow at the periphery of the hypoechoic mass.
gr4.jpg
PMC4900121_01_gr4.jpg
fig4
PMC4900121_02
24-year-old woman with hidradenitis suppurativa. Complex cystic lesion with peripheral blood flow in the left axilla with internal debris on longitudinal views using (A) grayscale and (B) color Doppler technique.
gr5.jpg
PMC4900121_02_gr5.jpg
fig5
On ultrasound, a complex cystic mass with intrinsic echogenic material and mild increased peripheral vascularity was identified just beneath the left axillary dermis (Fig. 5).